Pharmaceutical Data Integrity Remediation Consulting
- Overview
- Why Work With NSF?
- Benefits
When a company faces remediation, NSF offers the full range of services from gap assessments to remediation support.
Gap assessments help determine the scope of the problem and include:
- Addressing cultural root cause(s) of pharmaceutical data integrity issues
- Applying systemic data integrity remediation, which can be incorporated as part of the overall quality management system, using practical yet compliant solutions
- Providing training and education to all levels of an organization
- Supplying specific computer system expertise for compliance with 21 CFR Part 11 and EU Annex 11 required controls
We provide pharmaceutical remediation support for regulatory actions including:
- EU critical inspection findings
- EU statements of non-compliance
- U.S. 483s
- U.S. warning letters
- U.S. consent decrees
- U.S. Application Integrity Policy (AIP)
- U.S. import alerts (DWPE)
We can also provide a third-party data integrity expert to help you with your remediation efforts.
For more information about FDA and Health Canada related services in quality systems and compliance, email uspharma@nsf.org or call +1 202.822.1850.
For European and other international agencies, email pharmamail@nsf.org or call +44 1751 432 999.
Why Work With NSF?

Challenge: A large manufacturer in the southeastern U.S. that was under FDA consent decree contacted NSF about a pharmaceutical data integrity issue.
Solution: We served as the subject matter expert on FDA’s Application Integrity Policy (AIP), developed the FDA-approved application integrity audit plan protocol, determined the scope of issues and procedures for evaluating the company’s product evaluation, performed on-site New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) data verification, and provided ad hoc consulting on all aspects of the AIP and consent decree processes, including recommendations related to interactions with the FDA.
Benefits

Our data integrity audits, and the resulting pharmaceutical remediation plans, are trusted by pharmaceutical and biotech companies – and regulatory agencies – all over the world. Our unique blend of former regulatory agency inspectors and industry professionals ensures that you receive a thorough audit with no stone left unturned and sound, pragmatic recommendations for improvements and remediation.
-
NSF International Expands Health Sciences Group With Acquisition of Majority Interest in Amarex CRO
- 2 months ago
ANN ARBOR, Mich. - Global public health organization NSF International has acquired a majority interest in Amarex Clinical Research, LLC,...
-
NSF International and IDMA Repeat Successful Bangalore Pharmaceutical Quality Management Education
- 1 year ago
ANN ARBOR, Mich., YORK, UK and BANGALORE, India — NSF International, a global public health and safety organization, is again...
-
Lynne Byers and David Waddington Join NSF International’s Pharma Biotech Service in Europe
- 2 years ago
ANN ARBOR, Mich., USA and York, UK – NSF International, a global public health and safety organization, has appointed Lynne...
-
White Paper: Advantages of Excipient GMP Certification
-
White Paper: Data Integrity - Make Sure This Hot Topic Doesn’t Burn You
-
White Paper: Getting to the Bottom of Data Integrity
-
Webinar: Data Integrity – The Causes and Prevention
-
NSF Pharma Journal: Avoiding the Data Integrity Iceberg, Issue 32, 2015